|
NIAID-CDC Joint U.S. Partnership Implementing TB Elimination Research (JUPITER)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
Through weekly teleconferences, the Joint U.S. Partnership Implementing TB Elimination Research (JUPITER) facilitates cooperation, communication, and collaboration on tuberculosis between the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC). This approach helps ensure that Federal activities are coordinated and not duplicated, and stimulates collaborations where appropriate.
|
|
NIAID/CDC Dual Use Research of Concern (DURC) Risk Mitigation Reviews
|
Other
|
CDC
|
NIAID
|
The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins Division will provide technical assistance in evaluating the sufficiency of the biosecurity and/or biosafety measures incorporated into risk mitigation plans received from institutions, and cross-check risk mitigation plans and research conducted using select agents and toxins against information in the Federal Select Agent Program (FSAP) database.
|
|
NICHD Data Archiving and Specimen Hub (DASH) Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, HRSA
|
NICHD
|
The NICHD Director will consult the NICHD DASH Committee composed of NICHD staff with the appropriate policy knowledge. The Committee will provide oversight over the management and performance of NICHD DASH. Specialized sub-committees related to data submission, data access (such as the Data Access Committee), and quality control will report to the DASH Committee. In order to maintain policies consistent with evolving technological and ethical considerations, the NICHD Director will solicit, on an as needed basis, recommendations on the NICHD DASH Policy Statement from external experts representing public and scientific stakeholders through the NICHD Council. The NICHD DASH Committee will establish and maintain operating policies and procedures for NICHD DASH to address issues including, but not limited to: privacy and confidentiality of research participants, interests of individuals and groups, data submission procedures, data access and use procedures, and data security mechanisms based on the content and level of risk.
|
|
Nicotine Research Cigarettes (SPECTRUM)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
This partnership with the Food and Drug Administration (FDA) is for the production of produce research cigarettes.
|
|
NIH Biomarkers Consortium
|
Research Initiative
|
CMS, FDA
|
NIMH, NCATS, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDDK, NIEHS, NINDS
|
The National Institutes of Health (NIH) Biomarkers Consortium develops, validates, and qualifies biological markers (biomarkers) to speed the development of medicines and therapies for detection, prevention, diagnosis, and treatment of disease and to improve patient care. The Foundation for the National Institutes of Health (FNIH) coordinates and manages NIH participation in the consortium. The consortium encompasses research projects, ongoing working groups, as well as occasional workshops and conferences.
|
|
NIH Gabriella Miller Kids First Common Fund Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAID, NIAMS, NIDA, NIDCR, NIDDK, NIEHS, NINDS, OD/DPCPSI/ORIP, OD/DPCPSI/OSC
|
The NIH Gabriella Miller Kids First Common Fund Working Group supports the goals and initiatives of the NIH Gabriella Miller First Common Fund Pediatric Research Program. In fiscal year 2015, in accordance with the Gabriella Miller Kids First Research Act, Congress appropriated $12.6 million to the NIH Common Fund to support pediatric research. The Common Fund’s Gabriella Miller Kids First Pediatric Research program (Kids First) is developing a data resource for the pediatric research community of well-curated clinical and genetic sequence data that will allow scientists to identify genetic pathways that underlie specific pediatric conditions but that may also be shared between apparently disparate conditions.
|
|
NIH Guide for Grants and Contracts
|
Resource Development
|
AHRQ, CDC, FDA
|
OD/OER, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI
|
The National Institutes of Health (NIH) Guide for Grants and Contracts is the official publication for NIH medical and behavioral grant policies, guidelines, and funding opportunities. Other U. S. Department of Health and Human Services agencies also use the Guide to disseminate Funding Opportunity Announcements to its 58,000 subscribers.
|
|
NIH Precision Medicine Initiative (PMI) Policy group
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
OD/OSP, NCI, NHGRI, NIDA
|
This group was initially established in order to address policy recommendations in the report of the PMI Working Group of the Advisory Committee to the NIH Director. The group also met to identify and propose potential solutions to policy issues as they arose in the early course of the Precision Medicine Initiative Cohort Program (since renamed All of Us Research Program). The activities of this group were subsumed by the governance structure of the All of Us Research Program when it was established in mid-2016.
|
|
NIH Recombinant DNA Advisory Committee (RAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NCI, NHGRI, NIAID, NINDS
|
The Recombinant DNA Advisory Committee (RAC) advises the National Institutes of Health on the safe and ethical conduct of basic and clinical research involving recombinant DNA. It reviews protocols and provides recommendations for each protocol to enhance the scientific and ethical design. The RAC also discusses safety data and other emerging issues for the field of gene therapy. This year the RAC hosted a meeting to develop biosafety guidelines for gain-of-function research with H5N1 which led to the amendment of the NIH Guidelines for Research with Synthetic and Recombinant Research. The RAC also hosted a meeting of mid-level investigators to examine the scientific and other challenges that gene therapy will face in the next decade and a meeting to discuss optimization of the design of clinical trials using gene modified T cells in order to realize the potential of this immunotherapy while minimizing the risk to subjects.
|
|
NIH Translational Research Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, CC, CIT, CSR, NCATS, NCCIH, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/OER, OD/OIR, OD/OSP
|
As Chair of the National Institutes of Health (NIH) Translational Research Interest Group (TRIG), the National Cancer Institute (NCI) staff has coordinated Forums, Workshops, NIH Bench-to-Bedside Awardees’ Lecture Series, and Monthly Seminar Series to help bridge the gap between laboratory research and clinical applications; suggestions of topics and speakers for the Annual NIH Research Festivals; and nominations of speakers for the NIH Wednesday Afternoon Lecture Series and the NIH Director’s Lecture Series. NCI staff has informed TRIG members of scientific events coordinated with other NIH Scientific Interest Groups and Working Groups.
|